Product Information
FYREMADEL 250 MCG/0.5 ML SYR is a generic product labeled by Ferring Pharmaceuticals Inc., priced at $62.3467 per ML under NDC 55566101001. Its NADAC has been published 111 times since Aug 21, 2024.
FDA first approved this application on Nov 30, 2018. Its Orange Book therapeutic-equivalence code is AP.
Strength
250 ug/.5mL
Manufacturer
Ferring Pharmaceuticals Inc.NDC
55566101001
Classification
Generic
Dosage Form
INJECTION, SOLUTION
Route
SUBCUTANEOUS
Effective Date
12/17/2025
Active Ingredients
GANIRELIX ACETATEApproval Type
Generic (ANDA)
FDA Application
ANDA204246FDA Approved
11/30/2018
TE Code
AP
On Market Since
2/28/2022
Pharmacological Classes
Price Statistics
The NADAC for FYREMADEL 250 MCG/0.5 ML SYR has been published 111 times since Aug 21, 2024, and over the history we have for it it has declined 37.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $62.3467 per ML |
|---|---|
| All-time high | $100.4200 (Sep 11, 2024) |
| All-time low | $62.3467 (Dec 17, 2025) |
| 52-week high | $72.9180 |
| 52-week low | $62.3467 |
| Median price | $75.3895 |
| Average price | $77.4073 |
| Largest weekly change | -10.2% (Aug 20, 2025) |
| Weeks tracked | 111 |
| Tracking since | Aug 21, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the ganirelix acetate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Ferring Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
ganirelix acetate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Gonadotropin Releasing Hormone Receptor Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of FYREMADEL 250 MCG/0.5 ML SYR?
The current National Average Drug Acquisition Cost (NADAC) for FYREMADEL 250 MCG/0.5 ML SYR, manufactured by Ferring Pharmaceuticals Inc., is $62.3467 per ML (NDC 55566101001), effective Sep 30, 2026.
How has the price of FYREMADEL 250 MCG/0.5 ML SYR changed over time?
Over the history we have for it, the NADAC for FYREMADEL 250 MCG/0.5 ML SYR has declined 37.9%. It has been tracked across 111 weekly CMS publications since Aug 21, 2024.
What are the highest and lowest recorded NADAC prices for FYREMADEL 250 MCG/0.5 ML SYR?
Since Aug 21, 2024, the NADAC for FYREMADEL 250 MCG/0.5 ML SYR has ranged from a low of $62.3467 (Dec 17, 2025) to a high of $100.4200 (Sep 11, 2024), with a median of $75.3895 per ML.
Are there cheaper alternatives to FYREMADEL 250 MCG/0.5 ML SYR?
No other NADAC-published product currently shares the active ingredient and strength of FYREMADEL 250 MCG/0.5 ML SYR in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures FYREMADEL 250 MCG/0.5 ML SYR?
FYREMADEL 250 MCG/0.5 ML SYR (NDC 55566101001) is labeled by Ferring Pharmaceuticals Inc., and CMS classifies it as a generic product.